Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-1/COX-2 Inhibition, Gastropathy, and Gastroprotection Protocols

NSAID pharmacodynamics pivot upon the competitive enzymatic interruption of prostanoid synthesis:

• The Arachidonic Acid Cascade: Membrane phospholipids cleaved by phospholipase A2 yield arachidonic acid substrate, oxidized by cyclooxygenase (COX) heme-containing bifunctional enzymes into unstable PGH2, the precursor to all downstream prostanoids.
• Constitutive COX-1 Cytoprotection: Continuously expressed across gastric mucosa, endothelium, and platelets. In the stomach, COX-1-derived PGE2 and PGI2 maintain mucosal mucosal blood flow, stimulate mucus bicarbonate gel layer secretion, and suppress parietal acid output. In platelets, COX-1 exclusively generates pro-aggregatory thromboxane A2 (TXA2).
• Inducible COX-2 Pro-Inflammatory Dynamics: Rapidly upregulated by inflammatory cytokines (TNF-alpha, IL-1beta) at tissue injury foci, generating hyperalgesic prostaglandins that sensitize peripheral nociceptors and reset the hypothalamic thermal setpoint.
• Non-Selective NSAIDs vs Selective COX-2 Inhibitors (Coxibs): Traditional agents (naproxen, ibuprofen, diclofenac) block both isoforms. Coxibs (celecoxib, etoricoxib) preserve gastric mucosal protection but unbalance endothelial prostacyclin relative to platelet thromboxane, elevating atherothrombotic myocardial infarction risks.

Sustained systemic exposure to NSAIDs triggers multifaceted organ toxicity:

• NSAID-Induced Peptic Gastropathy: Suppressing mucosal PGE2 dissolves the protective mucus-bicarbonate physicochemical gel layer and impairs microvascular perfusion, allowing gastric HCl to digest underlying lamina propria. Asymptomatic subepithelial hemorrhages occur in >50% of users, progressing to clinical peptic ulcers and life-threatening bleeding.
• The Silent Perforation Hazard: Because NSAIDs exert systemic analgesia, catastrophic gastrointestinal ulcer bleeding or perforation frequently occurs without preceding dyspepsia, presenting emergently with sudden syncope, hematemesis, or melena in elderly patients.
• Hemodynamic Nephrotoxicity: Renal prostaglandins dilate afferent arterioles to maintain glomerular capillary filtration pressure. NSAIDs constrict afferent vessels, precipitating acute kidney injury (AKI), hyperkalemia, and sodium-mediated fluid retention.
• Cardiovascular and Hypertensive Derangements: NSAIDs destabilize blood pressure control (average elevation of 3–5 mmHg) and accelerate heart failure decompensation. Diclofenac exhibits a thrombotic cardiovascular hazard profile comparable to selective coxibs.

Evidence-based clinical prophylaxis prevents catastrophic gastrointestinal adverse events:

• High-Risk Patient Stratification: Age >65 years, prior history of peptic ulcer disease or hemorrhage, concurrent anticoagulant, corticosteroid, or antiplatelet therapy, high-dose/dual NSAID use, and untreated H. pylori colonization.
• Proton Pump Inhibitor (PPI) Co-Prescription: Standard co-therapy with once-daily morning PPIs (e.g., pantoprazole 20 mg, omeprazole 20 mg) elevates gastric pH, suppressing acid-peptic digestion and slashing NSAID ulcer incidence by >80%.
• Misoprostol (Prostaglandin E1 Analogue): Direct mucosal substitution restoring bicarbonate secretion and microcirculation; utilization is constrained by dose-dependent cramping diarrhea and strict contraindication in pregnancy (teratogenic abortifacient).
• Analgesic Step-Down and Topical Delivery: For non-inflammatory somatic pain, acetaminophen (paracetamol) remains the preferred baseline agent devoid of gastrointestinal toxicity. Topical transdermal NSAID formulations (gels, patches) provide equivalent localized joint analgesia with below 5% systemic bioavailability.